TDH: A Potential Drug Target for Neurodegenerative Disorders (G157739)

Target Name: TDH

NCBI ID: G157739

Content of Review Report on TDH Target / Biomarker

TDH

Other Name(s): FLJ25033 | L-threonine dehydrogenase (pseudogene) | SDR14E1P

TDH: A Potential Drug Target for Neurodegenerative Disorders

TDH (Tumor suppressor protein 25033) is a protein that is expressed in a variety of tissues throughout the body, including the brain, spleen, heart, and kidneys. It is a member of the superfamily of tumor suppressor proteins, which are a group of proteins that play a critical role in preventing cancer from developing.

TDH is a 21-kDa protein that is expressed in a variety of tissues throughout the body. It is highly expressed in the brain, where it is found in the enolase (AE) gene family. In the brain, TDH is primarily expressed in the frontal cortex, where it is involved in the development and maintenance of neural stem cells.

TDH has been shown to play a critical role in the development and progression of a variety of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. It is thought to function as a negative regulator of the TGF-β pathway, which is a well -known signaling pathway that is involved in the development and maintenance of tissues and organs.

One of the unique features of TDH is its ability to interact with a variety of different proteins, including the TGF-β1 receptor. This interaction between TDH and TGF-β1 is thought to play a critical role in the regulation of cellular processes that are involved in the development and maintenance of tissues and organs.

In addition to its role in the TGF-β pathway, TDH is also involved in the regulation of a variety of other cellular processes that are critical for the development and maintenance of tissues and organs. For example, it is known to play a role in the regulation of cell adhesion, and it is thought to be involved in the development of cancer.

TDH is also a potential drug target for a variety of diseases. For example, it is being targeted for use in the treatment of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. In addition, TDH is being investigated as a potential biomarker for a variety of diseases, including cancer and autoimmune diseases.

Overall, TDH is a protein that is expressed in a variety of tissues throughout the body and is involved in a variety of cellular processes that are critical for the development and maintenance of tissues and organs. Its role in the regulation of the TGF-β pathway and its potential as a drug target make it an important area of 鈥嬧?媟esearch for the study of a variety of diseases.

Protein Name: L-threonine Dehydrogenase (pseudogene)

The "TDH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TDH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets